BGC20-1531 a novel potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache

摘要

Background and purpose:Prostanoid EP4 receptor antagonists may have therapeutic utility in the treatment of migraine since EP4 receptors have been shown to be involved in prostaglandin (PG)E2-induced cerebral vascular dilatation, which may be an important contributor to migraine pain. This study reports the pharmacological characterization of BGC20-1531, a novel EP4 receptor antagonist.